Dr. Cunliffe, a TGen breast cancer investigator, starts 1-year
term today
PHOENIX, Ariz. - April 1, 2010 - Dr. Heather Cunliffe, a scientific
Investigator at the Translational Genomic Research Institute
(TGen), will join the board of directors of the Phoenix Affiliate
of Susan G. Komen for the Cure.
Dr. Cunliffe, the Head of TGen's Breast and Ovarian Cancer Research
Unit, begins her initial one-year term today on the 15-member board
of the local Komen for the Cure affiliate, one of 125 such
affiliates worldwide.
"I am incredibly grateful and humbled by my selection to this
outstanding board," Dr. Cunliffe said. "Representing TGen and its
efforts to leverage new discoveries in the diagnosis and treatment
of breast cancer, I look forward to a challenging and productive
term of contributing back to the community as one of the Phoenix
Affiliate board members."
Dr. Cunliffe, a recipient of a National Komen Research Grant in
2005, began a close relationship with executive leadership and
staff of Komen's Phoenix Affiliate, following her 2004 faculty
appointment at TGen.
"I have enjoyed participating in a variety of community outreach
events with the local Komen affiliate, including their signature
pink ribbon breakfasts, breast health awareness events, such as
Channel 12's Buddy Check 12, and of course, the annual Komen
Phoenix Race for the Cure," Dr. Cunliffe said.
Komen's Phoenix Affiliate today announced Dr. Cunliffe's
appointment along with its other 2010-11 Board of Directors, who
provide guidance and leadership to staff and the more than 1,500
local volunteers, working together for a cure for breast cancer.
The Phoenix Affiliate serves central and northern Arizona,
including Maricopa, Apache, Coconino, Gila, La Paz, Mohave, Navajo,
Pinal and Yavapai counties.
"At the national level, Susan G. Komen for the Cure has invested
nearly $450 million in 1,736 research projects aimed at securing
our vision of a world without breast cancer. Currently there are
over 759 active research projects reflecting a $298 million
investment," said Dan Costello, president of the Komen Phoenix
board of directors. "Having scientists like Dr. Cunliffe bring
these critical research dollars back to the Valley is a significant
benefit to our community and a tremendous contribution to the
identification and delivery of a cure for breast cancer."
The Phoenix Affiliate's signature fundraising and breast cancer
awareness event, the 18th Annual Komen Phoenix Race for the Cure,
will take place Sunday, Oct. 10, 2010, at the Arizona State
Capitol. Online registration is available at www.komenphoenix.org.
More than 30,000 participated in the 2009 event.
*
About Susan G. Komen for the Cure®
Nancy G. Brinker promised her dying sister, Susan G. Komen, she
would do everything in her power to end breast cancer forever. In
1982, that promise became Susan G. Komen for the Cure® and launched
the global breast cancer movement. Today, Komen for the Cure is the
world's largest grassroots network of breast cancer survivors and
activists fighting to save lives, empower people, ensure quality
care for all and energize science to find the cures. Thanks to
events like the Susan G. Komen Race for the Cure®, it has invested
more than $1 billion to fulfill that promise, becoming the largest
source of nonprofit funds dedicated to the fight against breast
cancer in the world. For more information about Susan G. Komen for
the Cure®, breast health or breast cancer, visit www.komen.org or
call 1-877 GO KOMEN.
About the Phoenix Affiliate of Susan G. Komen for the Cure®
The Phoenix Affiliate of Susan G. Komen for the Cure® - along with
those who generously support us with their talent, time and
resources - is working to better the lives of those facing breast
cancer in our community. We join more than 100,000 breast cancer
survivors and activists around the globe as part of the world's
largest and most progressive grassroots network fighting breast
cancer. Through events like the Susan G. Komen Phoenix Race for the
Cure®, we have invested over $13 million in local breast health and
breast cancer awareness projects in the nine counties of Central
and Northern Arizona, and breast cancer research. Up to 75 percent
of all funds generated by Komen Phoenix stay in the local area
while the remaining income goes to Komen for the Cure's Grants
Program supporting research, awards and educational and scientific
programs around the world. Join us by calling 602-544-CURE (2873)
or visiting us online at www.komenphoenix.org.
About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix,
Arizona-based non-profit organization dedicated to conducting
groundbreaking research with life changing results. Research at
TGen is focused on helping patients with diseases such as cancer,
neurological disorders and diabetes. TGen is on the cutting edge of
translational research where investigators are able to unravel the
genetic components of common and complex diseases. Working with
collaborators in the scientific and medical communities, TGen
believes it can make a substantial contribution to the efficiency
and effectiveness of the translational process. TGen is affiliated
with the Van Andel Research Institute in Grand Rapids, Michigan.
For more information, visit: www.tgen.org.
Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
[email protected]
# # #